Navigation Links
Covaris Installed Instrument Base Reaches 500 Units
Date:11/26/2008

WOBURN, Mass., Nov. 26 /PRNewswire/ -- Covaris Incorporated today announced that during the summer of 2008, the company celebrated the shipment of its 500th instrument unit and continued another successful year throughout 2008. To accommodate this rapid business growth, Covaris is both strengthening its sales and marketing organization as well as implementing a 50% expansion of its main facility.

The Covaris business was built upon the proprietary and patented AFA(TM) (Adaptive Focused Acoustics) technology. The AFA technology has the ability of impart both thermal and non-contact control of application processes, which, in many cases, could not be obtained prior to the development of AFA technology. This unique and sustainable competitive advantage enables Covaris to develop a broad range of applications in Genomics, Proteomics and Drug Discovery research.

"There has been an increased systematic acceptance of our technology over the past few years. We are pleased to see our sample preparation tools gaining market acceptance and incorporated into daily research investigations throughout research institutions and pharmaceutical companies, such as the Broad Institute, GlaxoSmithKline and Merck," said Jim Laugharn, President and CEO of Covaris, "with the help of our customers, we have developed and optimized solutions for various key applications, such as DNA shearing for next-gen sequencing, RNA extraction for gene expression profiling, analyte and small molecule extraction from difficult tissue samples, compound formulation, and ADME/Tox."

"I'm truly impressed with the solid technology and product platform Covaris has developed and its experienced team of people with well-balanced knowledge ranging from acoustic physics, mechanical engineering to biophysics and molecular biology," commented Jennifer Wu, the newly hired Director of Marketing, "I'm honored and excited to join Covaris to further ex
'/>"/>

SOURCE Covaris Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
2. Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility
3. Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc
4. Nanoscience Instruments, Inc. Introduces All-Diamond AFM Probes
5. Nikon Instruments Appoints LABSCO its Clinical Distributor in Six States
6. Instrumentation Laboratory Announces Passion & Results Awards Program
7. MKS Instruments Announces Third Quarter 2008 Earnings Conference Call
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. World Leader in Bench Top Flow Chemistry Instruments ThalesNano, Inc. Introduces an Industry First Seminar Series
10. Nanoscience Instruments, Inc. Announces Distribution of Nascatec's Complete Line of Unique AFM Probes and Sensors
11. World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... Dan Maher , Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in Miami ... ... , ... ... ...
(Date:3/17/2010)... Technologies recently launched a newly revised software program that will allow ... ... Orangeburg, NY (Vocus) March 17, 2010 -- DHS Technologies recently ... design their own unique shelter solution. , , , , ,VTAP ... allows users to simultaneously build 2-D and 3-D renderings of Deployable ...
(Date:3/16/2010)... 2010A Materials Design client and colleague ( www.materialsdesign.com ), ... R&D Center, has been honored with two GM R&D ... of Interfacial Tribology, Multi-scale Modeling of High-temperature Deformation in ... honor of John M. Campbell, a former scientific director ... his efforts to promote GM scientific research. The award ...
(Date:3/16/2010)... Foundation (GCF) and the Claudia Cohen Research Foundation announce today that Dr. Paul ... GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher.  The prize is being presented at ... San Francisco March 14-17, 2010 . , ... ... , ...
Breaking Biology Technology:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2BioMarin to Present at the Barclays Capital Global Healthcare Conference 3DHS Technologies Launches VTAP 2.0 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5
... April 30 Tigris Pharmaceuticals, Inc., a privately held ... on its novel molecule, AFP-464, during the recent AACR ... represents a significant advancement in the treatment of Triple ... of invasive breast cancer," stated Edmundo Muniz, M.D., Ph.D., ...
... Educational Webinar "How Organizations Can Make the Transition to ... Virtify, Inc. , , CAMBRIDGE, Mass., April ... the market leader in Enterprise Content Compliance solutions for ... ), a provider of Enterprise Compliance and Quality Management ...
... 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... for the first quarter ended March 31, 2009. , ... first quarter in what has been a difficult business ... and CEO of Angiotech. "Sales in our proprietary Surgical ...
Other Biology Technology:Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 2Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 3Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 4Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes' 2Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes' 3Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009 21
(Date:3/16/2010)... D.C., March 16, 2010 Primary care physicians agree ... they do not have the right weight management resources. ... loss, but adults who need to lose weight may ... These findings and others come from new research ... and Prevent (STOP) Obesity Alliance. , In a ...
(Date:3/16/2010)... resistance to sea lice treatments such as the ... was observed. Pyrethroid use still increased from 2008 ... Older sea lice treatments are being used again ... teflubenzuron. Hydrogen peroxide, which has not been used ... mainly under controlled conditions in wellboats. , The ...
(Date:3/16/2010)... major report by an international research team explores the ... the economy and human health. , Global meat production ... double its present level by 2050, according to a ... team of scientists and policy experts. The impact of ... for human health, the environment and the global economy, ...
Breaking Biology News(10 mins):STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 2STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 3Major report reveals the environmental and social impact of the 'livestock revolution' 2Major report reveals the environmental and social impact of the 'livestock revolution' 3Major report reveals the environmental and social impact of the 'livestock revolution' 4Abbott Hosts Conference Call for Second Quarter Earnings 49896 1RIEMSER Announces Upcoming Chicago Bone Grafting Workshop 49894 1RIEMSER Announces Upcoming Chicago Bone Grafting Workshop 49894 2Stay Upbeat Active to Keep the Mind Young 49889 1Stay Upbeat Active to Keep the Mind Young 49889 2Stay Upbeat Active to Keep the Mind Young 49889 3
... Laboratory (CSHL) will play a central role in an ... the National Science Foundation (NSF). The Collaborative will define ... have global implications. , The idea is to ... transform the way plant science is done, and that ...
... has awarded a University of Arizonaled team $50 million ... within which to answer plant biology,s grand challenge questions, ... has the capacity to address. The project will unite ... the world for the first time ever to provide ...
... of complex, three-dimensional nanoscale structures and the ability ... now possible with a process developed by researchers ... the rapid evaporation of solvent from simple inks, ... nanofibers, stacked arrays of nanofibers and continuously wound ...
Other Biology News:Cold Spring Harbor Laboratory to play central role addressing key questions in plant biology 2Cold Spring Harbor Laboratory to play central role addressing key questions in plant biology 3UA-led research team awarded $50 million to solve plant biology's grand challenge questions 2UA-led research team awarded $50 million to solve plant biology's grand challenge questions 3UA-led research team awarded $50 million to solve plant biology's grand challenge questions 4UA-led research team awarded $50 million to solve plant biology's grand challenge questions 5New process makes nanofibers in complex shapes and unlimited lengths 2